<DOC>
	<DOCNO>NCT01936636</DOCNO>
	<brief_summary>This Observational Registry study design collect self-reported Transmucosal Immediate Release Fentanyl ( TIRF ) Risk Evaluation Mitigation Strategy ( REMS ) Access program-enrolled patient experience breakthrough cancer pain ( BTcP ) result treatment Abstral® use Quality Life pain measurement tool administer via questionnaire .</brief_summary>
	<brief_title>Observational Registry Study Quality Life When Treating BTcP With Abstral</brief_title>
	<detailed_description>This post-marketing , single arm , open label multicenter trial assess Abstral ( fentanyl ) Sublingual Tablets breakthrough cancer pain ( BTcP ) opioid-tolerant cancer patient . - Prior study enrollment , patient enrollment TIRF REMS Access program must confirm . - Eligible patient sign write informed consent . Patients proxy witness must able sign write informed consent participate study ; patient may use proxy caregiver assist completion study questionnaire . - Day 0 , study site must enroll patient complete patient demographic profile ( de-identified ) . - Day 0 , patient instruct use questionnaire . - Day 0 , patient complete baseline questionnaire leave physician office . - On study Days 14 , 21 , 28 ( ±3 day ) patient questionnaire complete patient ( caregiver proxy ) via secure online data entry portal . - For patient complete paper questionnaire , within 1 month day 28 , patient return complete questionnaire via mail , fax hand carry study site coordinator processing . - Patient consider complete study successfully complete questionnaire receive CRO within appropriate time limit .</detailed_description>
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>All patient 18 year age old breakthrough cancer pain register Transmucosal Immediate Release Fentanyl ( TIRF ) Risk Evaluation Mitigation Strategy ( REMS ) Access program receiving Abstral® direction TIRF REMS Access programregistered physician eligible study . Patients proxy witness must able sign write informed consent participate study ; patient may also use proxy caregiver assist completion study questionnaire . No patient enrol prescribed Abstral BTcP compliance Transmucosal Immediate Release Fentanyl ( TIRF ) Risk Evaluation Mitigation Strategy ( REMS ) Access program guideline . No patient may enrol contraindication receive Abstral pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Breakthrough cancer pain</keyword>
	<keyword>diary</keyword>
	<keyword>quality life</keyword>
	<keyword>Abstral</keyword>
	<keyword>BTcP</keyword>
</DOC>